Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maxigesic PE is a patented, fixed-dose combination small molecule drug developed by AFT Pharmaceuticals. It contains three active ingredients: paracetamol (acetaminophen), ibuprofen, and phenylephrine. Paracetamol acts centrally to relieve pain and reduce fever; ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes to reduce inflammation and pain; and phenylephrine is an alpha-1 adrenergic receptor agonist that acts as a nasal decongestant. The drug is indicated for the temporary relief of pain and nasal congestion associated with cold, flu, and sinus conditions, including headache, fever, inflammation, body aches, sore throat, and blocked or runny nose. It is formulated as an oral tablet and is available over the counter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + paracetamol + phenylephrine.